due
abil
inhibit
viral
dna
rna
replic
nucleosid
analogu
use
decad
potent
antivir
therapeut
howev
one
major
limit
nucleosid
analogu
develop
antivir
resist
regard
flexibl
nucleosid
analogu
known
flexim
garner
attent
year
due
abil
survey
differ
amino
acid
enzym
bind
site
thu
overcom
potenti
develop
antivir
resist
acycl
flexim
previous
demonstr
antivir
activ
numer
virus
includ
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
ebov
recent
flavivirus
dengu
denv
yellow
fever
viru
yfv
due
interest
result
structur
activ
relationship
sar
studi
pursu
order
analyz
effect
pyrimidin
function
group
acyl
protect
group
antivir
activ
cytotox
conform
result
studi
present
herein
nucleosid
analogu
long
serv
cornerston
antivir
therapeut
due
abil
inhibit
viral
dna
rna
replic
alter
differ
compon
nucleosid
nucleobas
sugar
moieti
phosphat
group
medicin
chemist
develop
novel
analogu
use
variou
therapeut
past
decad
research
seleyradtk
lab
focus
develop
variou
type
flexibl
nucleosid
analogu
call
flexim
demonstr
abil
overcom
point
mutat
within
bind
site
biolog
signific
enzym
figur
flexim
featur
purin
ring
split
imidazol
pyrimidin
compon
remain
connect
singl
carboncarbon
bond
imidazol
pyrimidin
distal
flexim
imidazol
pyrimidin
proxim
flexim
strateg
design
endow
flexim
inher
flexibl
retain
hydrogen
bond
motif
necessari
enzym
recognit
adapt
flexibl
bind
site
environ
allow
access
differ
amino
acid
enzym
bind
site
previous
unattain
rigid
parent
nucleosid
recent
studi
within
seleyradtk
lab
focus
develop
flexim
analogu
use
antivir
anticanc
therapeut
particular
flexim
analogu
base
structur
food
drug
administr
fda
approv
drug
acyclovir
demonstr
great
promis
compound
demonstr
low
micromolar
activ
coronavirus
filovirus
recent
flavivirus
figur
unpublish
result
parallel
secondari
seri
featur
methoxi
pyrimidin
develop
order
better
analyz
effect
hydrogen
bond
motif
antivir
activ
seri
also
test
aforement
virus
howev
analogu
activ
compound
furthermor
addit
acet
protect
group
led
decreas
antivir
activ
also
larg
decreas
cytotox
unpublish
result
order
explor
effect
differ
hydrogen
bond
donor
acceptor
group
flexim
pyrimidin
ring
well
effect
variou
acet
protect
group
antivir
activ
sar
studi
pursu
herein
report
synthesi
antivir
evalu
seri
figur
recent
studi
within
seleyradtk
lab
focus
develop
flexim
analogu
use
antivir
anticanc
therapeut
particular
flexim
analogu
base
structur
food
drug
administr
fda
approv
drug
acyclovir
demonstr
great
promis
compound
demonstr
low
micromolar
activ
coronavirus
filovirus
recent
flavivirus
recent
studi
within
seleyradtk
lab
focus
develop
flexim
analogu
use
antivir
anticanc
therapeut
particular
flexim
analogu
base
structur
food
drug
administr
fda
approv
drug
acyclovir
demonstr
great
promis
compound
demonstr
low
micromolar
activ
coronavirus
filovirus
recent
flavivirus
figur
unpublish
result
parallel
secondari
seri
featur
methoxi
pyrimidin
develop
order
better
analyz
effect
hydrogen
bond
motif
antivir
activ
seri
also
test
aforement
virus
howev
analogu
activ
compound
furthermor
addit
acet
protect
group
led
decreas
antivir
activ
also
larg
decreas
cytotox
unpublish
result
order
explor
effect
differ
hydrogen
bond
donor
acceptor
group
flexim
pyrimidin
ring
well
effect
variou
acet
protect
group
antivir
activ
sar
studi
pursu
herein
report
synthesi
antivir
evalu
seri
figur
parallel
secondari
seri
featur
methoxi
pyrimidin
develop
order
better
analyz
effect
hydrogen
bond
motif
antivir
activ
seri
also
test
aforement
virus
howev
analogu
activ
compound
furthermor
addit
acet
protect
group
led
decreas
antivir
activ
also
larg
decreas
cytotox
unpublish
result
order
explor
effect
differ
hydrogen
bond
donor
acceptor
group
flexim
pyrimidin
ring
well
effect
variou
acet
protect
group
antivir
activ
sar
studi
pursu
herein
report
synthesi
antivir
evalu
seri
synthesi
analogu
began
modifi
acycl
sugar
moieti
addit
differ
acyl
protect
group
scheme
synthesi
previous
publish
group
intermedi
obtain
similar
fashion
addit
appropri
anhydrid
follow
triethylamin
diisopropylamin
dipea
anh
give
clear
pale
yellow
oil
high
yield
synthesi
alreadi
report
remain
analogu
seri
pursu
first
use
appropri
stannyl
pyrimidin
stile
condit
prac
buac
prac
buac
realiz
good
yield
scheme
scheme
reagent
condit
acet
anhydrid
propion
anhydrid
isobutyr
anhydrid
trimethylacet
anhydrid
triethylamin
tea
dipea
anh
rt
synthesi
analogu
began
modifi
acycl
sugar
moieti
addit
differ
acyl
protect
group
scheme
synthesi
previous
publish
group
intermedi
obtain
similar
fashion
addit
appropri
anhydrid
follow
triethylamin
diisopropylamin
dipea
anh
ch
cl
give
clear
pale
yellow
oil
high
yield
synthesi
analogu
began
modifi
acycl
sugar
moieti
addit
differ
acyl
protect
group
scheme
synthesi
previous
publish
group
intermedi
obtain
similar
fashion
addit
appropri
anhydrid
follow
triethylamin
diisopropylamin
dipea
anh
give
clear
pale
yellow
oil
high
yield
synthesi
alreadi
report
remain
analogu
seri
pursu
first
use
appropri
stannyl
pyrimidin
stile
condit
prac
buac
prac
buac
realiz
good
yield
scheme
scheme
reagent
condit
acet
anhydrid
propion
anhydrid
isobutyr
anhydrid
trimethylacet
anhydrid
triethylamin
tea
dipea
anh
rt
scheme
reagent
condit
acet
anhydrid
propion
anhydrid
isobutyr
anhydrid
trimethylacet
anhydrid
triethylamin
tea
dipea
anh
ch
cl
rt
synthesi
alreadi
report
remain
analogu
seri
pursu
first
use
appropri
stannyl
pyrimidin
stile
condit
prac
buac
prac
buac
realiz
good
yield
scheme
seri
success
synthes
seri
pursu
similar
previou
seri
synthesi
seri
start
commerci
avail
bi
tributyltin
give
stannyl
pyrimidin
good
yield
scheme
follow
purif
stannyl
pyrimidin
still
palladium
catalyz
crosscoupl
method
employ
realiz
compound
buac
high
yield
compar
previou
seri
analogu
compar
averag
seri
final
seri
origin
pursu
use
similar
method
start
commerci
avail
scheme
use
niodosuccinimid
glacial
acet
acid
realiz
follow
addit
bi
tributyltin
give
stannyl
coupl
partner
subsequ
coupl
gave
low
yield
gave
rise
purif
issu
difficult
isol
pure
product
without
residu
tin
impur
product
also
fairli
solubl
water
thu
use
potassium
fluorid
kf
wash
convert
solubl
tin
impur
insolubl
unsuccess
furthermor
addit
acyl
protect
group
effect
tin
impur
remov
thu
deprotect
give
methanol
ammonia
ineffect
well
protect
group
envis
attempt
make
purif
facil
increas
overal
yield
first
protect
group
tri
use
two
equival
ditertbutyl
dicarbon
give
diboc
protect
amin
could
easili
deprotect
coupl
sugar
use
mild
acid
condit
scheme
use
niodosuccinimid
glacial
acet
acid
realiz
follow
addit
bi
tributyltin
give
stannyl
coupl
partner
subsequ
coupl
gave
low
yield
gave
rise
purif
issu
difficult
isol
pure
product
without
residu
tin
impur
product
also
fairli
solubl
water
thu
use
potassium
fluorid
kf
wash
convert
solubl
tin
impur
insolubl
snbu
f
unsuccess
furthermor
addit
acyl
protect
group
effect
tin
impur
remov
thu
deprotect
give
methanol
ammonia
ineffect
well
protect
group
envis
attempt
make
purif
facil
increas
overal
yield
first
protect
group
tri
use
two
equival
ditertbutyl
dicarbon
give
diboc
protect
amin
could
easili
deprotect
coupl
sugar
use
mild
acid
condit
scheme
protect
intermedi
use
ditertbutyl
dicarbon
success
produc
diboc
compound
howev
subsequ
attempt
instal
stannyl
compon
unsuccess
furthermor
attempt
instal
boron
ester
use
mild
suzuki
coupl
condit
also
unsuccess
final
attempt
employ
diboc
protect
group
tri
protect
stannyl
pyrimidin
howev
method
also
prove
ineffect
attent
turn
toward
use
situ
protect
amin
group
follow
negishi
condit
prac
buac
compound
condit
previous
success
flexim
develop
lab
scheme
impur
insolubl
unsuccess
furthermor
addit
acyl
protect
group
effect
tin
impur
remov
thu
deprotect
give
methanol
ammonia
ineffect
well
protect
group
envis
attempt
make
purif
facil
increas
overal
yield
first
protect
group
tri
use
two
equival
ditertbutyl
dicarbon
give
diboc
protect
amin
could
easili
deprotect
coupl
sugar
use
mild
acid
condit
scheme
protect
intermedi
use
ditertbutyl
dicarbon
success
produc
diboc
compound
howev
subsequ
attempt
instal
stannyl
compon
unsuccess
furthermor
attempt
instal
boron
ester
use
mild
suzuki
coupl
condit
also
unsuccess
final
attempt
employ
diboc
protect
group
tri
protect
stannyl
pyrimidin
howev
method
also
prove
ineffect
attent
turn
toward
use
situ
protect
amin
group
follow
negishi
condit
prac
buac
compound
condit
previous
success
flexim
develop
lab
scheme
compound
first
protect
situ
chlorotrimethylsilan
give
intermedi
subsequ
complex
give
intermedi
dropwis
addit
zinc
complex
either
gave
prac
buac
respect
coupl
went
well
later
purif
analogu
prove
difficult
howev
addit
chromatographi
gradient
greatli
decreas
streak
allow
purif
product
yield
differ
seri
complet
sent
test
collabor
center
diseas
control
cdc
test
ebov
briefli
recombin
report
viru
ebovmakona
express
zsgreen
rebovzsg
use
infect
compoundtr
cell
multipl
infect
moi
three
day
later
zsgreen
fluoresc
measur
valu
determin
concurr
compound
effect
cell
viabil
determin
measur
cellular
atp
content
compoundtr
mockinfect
cell
result
studi
summar
tabl
none
analogu
test
demonstr
cytotox
compound
remain
activ
ebov
interest
trend
emerg
regard
acyl
protect
group
well
moieti
pyridmin
ring
parent
compound
seri
test
found
chang
hydrogen
bonddon
amino
group
compound
hydrogen
bondaccept
methoxi
compound
first
protect
situ
chlorotrimethylsilan
give
intermedi
subsequ
complex
zncl
give
intermedi
dropwis
addit
zinc
complex
either
gave
prac
buac
respect
coupl
went
well
later
purif
analogu
prove
difficult
howev
addit
nh
oh
ch
oh
chromatographi
gradient
greatli
decreas
streak
allow
purif
product
differ
seri
complet
sent
test
collabor
center
diseas
control
cdc
test
ebov
briefli
recombin
report
viru
ebovmakona
express
zsgreen
rebovzsg
use
infect
compoundtr
cell
multipl
infect
moi
three
day
later
zsgreen
fluoresc
measur
valu
determin
concurr
compound
effect
cell
viabil
determin
measur
cellular
atp
content
compoundtr
mockinfect
cell
result
studi
summar
tabl
none
analogu
test
demonstr
cytotox
compound
remain
activ
ebov
interest
trend
emerg
regard
acyl
protect
group
well
moieti
pyridmin
ring
parent
compound
seri
test
found
chang
hydrogen
bonddon
amino
group
compound
hydrogen
bondaccept
methoxi
group
compound
decreas
activ
compar
p
furthermor
hydrogen
atom
compound
decreas
activ
compar
compound
also
observ
compar
p
compound
featur
amino
group
respect
display
activ
ebov
interestingli
activ
could
recov
seri
well
improv
seri
alter
acyl
protect
group
instanc
addit
acet
protect
group
greatli
increas
activ
compar
parent
analogu
compar
p
howev
addit
acyl
protect
group
seem
affect
seri
differ
compound
activ
ebov
contrast
parent
compound
activ
activ
ebov
ec
wherea
parent
compound
activ
seri
activ
appear
increas
reach
statist
signific
p
seri
loss
activ
ethyl
acyl
etac
analogu
compar
analogu
acet
group
compar
well
compar
howev
activ
return
isopropyl
acyl
prac
protect
compound
final
tertbutyl
acyl
buac
protect
analogu
variabl
activ
across
seri
though
part
analogu
significantli
differ
activ
acet
ac
adenosin
seri
activ
except
buac
demonstr
weak
activ
result
along
potent
activ
observ
compound
also
bear
group
suggest
group
import
determin
antivir
activ
differ
activ
ac
etac
prac
interest
trend
etac
analogu
consist
least
activ
analogu
order
analyz
trend
due
chang
lipophil
due
branch
logp
valu
determin
analogu
tabl
logp
valu
common
measur
lipophil
greater
valu
lipophil
compound
surprisingli
parent
analogu
r
group
h
least
lipophil
seri
amino
seri
demonstr
lowest
lipophil
averag
differ
parent
analogu
acet
analogu
r
ac
substanti
howev
ethyl
acyl
analogu
r
etac
substanti
lipophil
acet
analogu
exampl
compar
seri
surprisingli
increas
branch
also
led
increas
lipophil
buac
analogu
lipophil
seri
increas
lipophil
typic
associ
better
drug
candid
limit
increas
lipophil
affect
potenc
instanc
isopropyl
acyl
analogu
prac
demonstr
ec
ebov
logp
wherea
buac
ec
logp
furthermor
isopropyl
acyl
analogu
prac
demonstr
ec
logp
wherea
buac
ec
logp
suggest
compound
logp
valu
lipophil
thu
less
activ
ebov
interestingli
compound
prac
less
activ
branch
buac
less
lipophil
logp
vs
suggest
compound
logp
valu
greater
may
activ
togeth
result
suggest
lipophil
branch
affect
antivir
activ
previou
studi
seleyradtk
lab
found
solut
ribos
flexim
prefer
typic
anticonform
found
nucleosid
studi
pursu
order
determin
acycl
flexim
analogu
also
prefer
anticonform
solut
hnmr
spectra
record
nmr
spectromet
concentr
dimethylsulfoxid
dmso
use
wellresolv
nmr
signal
aromat
proton
figur
assess
conform
prefer
along
torsion
angl
possibl
use
nuclear
overhaus
effect
spectroscopi
noesi
experi
previou
studi
seleyradtk
lab
found
solut
ribos
flexim
prefer
typic
anticonform
found
nucleosid
studi
pursu
order
determin
acycl
flexim
analogu
also
prefer
anticonform
solut
hnmr
spectra
record
nmr
spectromet
concentr
dimethylsulfoxid
dmso
use
wellresolv
nmr
signal
aromat
proton
figur
assess
conform
prefer
along
torsion
angl
possibl
use
nuclear
overhaus
effect
spectroscopi
noesi
experi
select
invers
proton
result
strong
noe
enhanc
wherea
noe
enhanc
rel
weak
figur
lack
strong
noe
select
invers
proton
result
strong
noe
enhanc
wherea
noe
enhanc
rel
weak
figur
lack
strong
noe
enhanc
suggest
antiorient
along
torsion
angl
predomin
conform
compound
solut
addit
invers
proton
show
noe
enhanc
figur
confirm
spatial
apart
overal
support
anticonform
studi
also
found
compound
also
favor
anticonform
along
torsion
angl
interestingli
select
invers
proton
compound
result
rel
strong
noe
enhanc
well
moder
noe
enhanc
figur
result
suggest
syn
orient
along
torsion
angl
predomin
conform
also
determin
promin
acet
prodrug
result
particularli
interest
due
lack
antivir
activ
seen
seri
ebov
differ
conform
compound
may
offer
reason
drastic
differ
antivir
activ
observ
differ
orient
particularli
highlight
figur
compound
analyz
studi
interest
see
seri
seri
also
demonstr
differ
orient
compar
seri
due
antivir
activ
found
seri
expect
analogu
also
predomin
found
anticonform
reaction
perform
use
ovendri
glasswar
nitrogen
atmospher
magnet
stir
reagent
purchas
sigmaaldrich
rockvil
md
usa
alfa
aesar
haverhil
usa
combiblock
san
diego
ca
usa
solvent
either
purchas
anhydr
dri
use
mbraun
solvent
purif
system
mbsp
mbraun
stratham
nh
usa
reaction
monitor
thin
layer
chromatographi
tlc
use
emd
silica
gel
coat
glassback
tlc
plate
milliporesigma
rockvil
md
usa
result
particularli
interest
due
lack
antivir
activ
seen
seri
ebov
differ
conform
compound
may
offer
reason
drastic
differ
antivir
activ
observ
differ
orient
particularli
highlight
figur
result
particularli
interest
due
lack
antivir
activ
seen
seri
ebov
differ
conform
compound
may
offer
reason
drastic
differ
antivir
activ
observ
differ
orient
particularli
highlight
figur
compound
analyz
studi
interest
see
seri
seri
also
demonstr
differ
orient
compar
seri
due
antivir
activ
found
seri
expect
analogu
also
predomin
found
anticonform
reaction
perform
use
ovendri
glasswar
nitrogen
atmospher
compound
analyz
studi
interest
see
seri
seri
also
demonstr
differ
orient
compar
seri
due
antivir
activ
found
seri
expect
analogu
also
predomin
found
anticonform
reaction
perform
use
ovendri
glasswar
nitrogen
atmospher
magnet
stir
reagent
purchas
sigmaaldrich
gener
procedur
acylprotect
sugar
solut
g
mmol
anh
ch
cl
ml
nitrogen
balloon
ad
correspond
anhydrid
equival
triethylamin
ml
mmol
dmap
g
mmol
stir
room
temperatur
reaction
stir
hour
room
temperatur
solvent
remov
vacuo
purif
flash
column
chromatographi
silica
gave
product
good
yield
character
methoxi
ethyl
pival
anhydrid
use
trimethylacet
anhydrid
ml
mmol
crude
mixtur
purifi
flash
column
chromatographi
silica
etoac
hexan
give
product
clear
oil
gener
procedur
still
cross
coupl
sugar
equival
stannyl
reagent
equival
dri
threeneck
flash
vacuo
two
hour
suspend
anh
dmf
ml
direct
nitrogen
bubbl
csf
equival
cui
equival
ad
reaction
stir
min
tetraki
equival
ad
reaction
heat
c
stir
direct
nitrogen
bubbl
h
complet
reaction
cool
solvent
remov
vacuo
crude
mixtur
purifi
three
four
time
flash
column
chromatographi
silica
give
pure
product
methoxi
ethyl
isobutyr
prac
sugar
g
mmol
tributylstannyl
pyrimidin
g
mmol
use
product
purifi
twice
time
flash
column
chromatographi
silica
etoac
hexan
give
product
light
orang
oil
g
h
nmr
mhz
cdcl
j
hz
j
hz
j
hz
solut
g
mmol
anh
ch
oh
ml
nitrogen
ad
naom
weight
ch
oh
ml
mmol
room
temperatur
reaction
stir
room
temperatur
nitrogen
hour
upon
complet
solvent
remov
vacuo
give
yellow
solid
crude
mixtur
purifi
flash
column
chromatographi
silica
etoac
hexan
give
product
white
solid
tributylstannyl
pyrimidin
solut
g
mmol
anh
dmf
ml
direct
nitrogen
bubbl
ad
bi
tributyltin
ml
mmol
pd
dba
g
mmol
reaction
stir
c
h
complet
reaction
cool
room
temperatur
solvent
remov
vacuo
give
black
oil
crude
mixtur
resuspend
etoac
ml
filter
celit
pad
filtrat
concentr
vacuo
give
brown
oil
crude
product
purifi
flash
column
chromatographi
silica
etoac
hexan
give
pure
product
pale
yellow
oil
methoxi
ethyl
acet
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
three
time
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
pale
yellowwhit
solid
g
methoxi
ethyl
propion
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
three
time
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
pale
yellow
oil
g
methoxi
ethyl
isobutyr
prac
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
three
time
flash
column
chromatographi
silica
first
purif
etoac
hexan
subsequ
purif
ch
oh
ch
cl
give
product
pale
yellow
oil
g
methoxi
ethyl
pival
buac
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
three
time
flash
column
chromatographi
silica
first
purif
etoac
hexan
subsequ
purif
ch
oh
ch
cl
give
product
clear
oil
g
h
nmr
mhz
cd
od
solut
g
mmol
anh
dmf
ml
direct
nitrogen
bubbl
ad
bi
tributyltin
ml
mmol
pd
dba
g
mmol
reaction
heat
c
stir
h
direct
nitrogen
bubbl
complet
solvent
remov
vacuo
give
black
thick
oil
crude
mixtur
resuspend
etoac
filter
celit
pad
filtrat
concentr
vacuo
give
dark
liquid
purif
perform
use
flash
column
chromatographi
silica
etoac
hexan
give
pure
product
yellow
oil
g
r
f
methoxi
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
four
time
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
pale
pink
solid
g
methoxi
ethyl
acet
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
three
time
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
white
solid
g
methoxi
ethyl
isobutyr
prac
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
four
time
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
pink
solid
g
methoxi
ethyl
pival
buac
sugar
g
mmol
stannyl
pyrimidin
g
mmol
use
product
purifi
twice
flash
column
chromatographi
silica
ch
oh
ch
cl
give
product
white
solid
g
h
nmr
mhz
cdcl
br
j
hz
j
hz
solut
g
mmol
glacial
acoh
ml
nitrogen
ad
niodosuccinimid
g
mmol
stir
reaction
reflux
c
two
hour
upon
complet
reaction
cool
room
temperatur
solvent
remov
vacuo
result
yellow
solid
resuspend
etoac
quench
nahco
ml
wash
na
ml
organ
layer
dri
mgso
graviti
filter
give
yellow
solid
crude
product
purifi
flash
column
chromatographi
silica
ch
oh
ch
cl
give
pure
product
pale
yellow
solid
g
r
f
etoac
hex
spectral
data
agreement
literatur
valu
solut
g
mmol
anh
dmf
ml
direct
bubbl
nitrogen
ad
bi
tributyl
tin
ml
mmol
pd
dba
studi
sar
pursu
order
increas
antivir
activ
ebov
decreas
cytotox
none
analogu
analyz
cytotox
none
analogu
activ
ebov
compound
regardless
determin
seri
overal
activ
seri
suggest
moieti
may
import
activ
furthermor
compound
logp
valu
greater
less
offer
necessari
lipophil
activ
also
found
compound
within
seri
adopt
typic
anticonform
wherea
compound
within
seri
adopt
syn
conform
thu
offer
anoth
possibl
explan
differ
antivir
activ
initi
result
hand
synthesi
addit
analogu
especi
methoxi
group
posit
consid
order
continu
tri
explor
antivir
activ
result
studi
report
elsewher
becom
avail
